https://gphjournal.org/index.php/bs <p style="font-family: 'Segoe UI', sans-serif; font-size: 16px; color: #333;"><strong>GPH-International Journal of Biological &amp; Medicine Science (e-ISSN&nbsp;<a href="https://portal.issn.org/resource/ISSN/3050-9610" target="_blank" rel="noopener">3050-9610</a>)</strong> is a peer-reviewed, open-access journal dedicated to advancing research in the biological and medical sciences. The journal publishes original research articles, comprehensive reviews, and innovative case studies covering topics such as biotechnology, clinical research, biomedical engineering, and healthcare innovations. By fostering interdisciplinary collaboration and promoting the translation of scientific discoveries into practical medical applications, the journal provides a global platform for enhancing public health and advancing life sciences.</p> Global Publication House en-US GPH-International Journal of Biological & Medicine Science 3050-9610 <p>Author(s) and co-author(s)&nbsp;jointly&nbsp;and severally represent and warrant that the Article is original with the author(s) and does not infringe any&nbsp;copyright or violate any other right of any third parties, and that the Article has not been published&nbsp;elsewhere.&nbsp;Author(s) agree to the terms that the <strong>GPH Journal</strong> will have the full right to remove the published article on any misconduct found in the published article.</p> https://gphjournal.org/index.php/bs/article/view/2530 <p><strong>Background</strong>: Oxidative stress contributes to multiple sclerosis (MS) pathogenesis, and serum uric acid (SUA) is a potent endogenous antioxidant. Serum uric acid (SUA), have therefore become a topic of scientific interest due to their potential modulatory role in CNS injury including multiple sclerosis.&nbsp;</p> <p><strong>Methods:</strong> In this case–control study, 44 patients with MS and 44 age- and sexmatched healthy controls were evaluated. SUA levels were measured using enzymatic methods. Associations between SUA levels and demographic variables, disability (Expanded Disability Status Scale, EDSS), disease duration, ambulation status, and disease-modifying therapies (DMTs) were analyzed using ANOVA and regression models adjusted for age, sex, and renal function.</p> <p><strong>Results</strong>: MS patients exhibited significantly lower SUA levels compared to healthy controls (p &lt; 0.05). SUA levels were not significantly associated with EDSS scores, disease duration, or ambulation status. While DMT exposure influenced SUA levels overall, no significant pairwise differences were observed between specific drugs.</p> <p><strong>Conclusion</strong>: These findings support the potential utility of SUA as a diagnostic biomarker in MS and as a marker of treatment response to DMTs. However, SUA levels do not correlate with disease duration or physical disability (EDSS).</p> Mustafa Makki Ajam Mustafa Falah Hamza Salam F. Mohammed Rabeea ##submission.copyrightStatement## https://creativecommons.org/licenses/by-nc-nd/4.0 2026-06-30 2026-06-30 9 6 01 09 10.5281/zenodo.21675307